ABLi Therapeutics

Executive Summary

ABLi Therapeutics is a private biotechnology company developing first-in-class, brain-penetrant small molecule inhibitors of Abelson tyrosine kinases (Abl kinases) for Parkinson's disease and related neurodegenerative disorders. Leveraging its proprietary RAMP™ drug innovation engine, ABLi re-engineers kinase inhibitors to achieve superior brain exposure, potency, and safety, aiming to intervene at the root of disease pathology. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. While still in preclinical stages, ABLi's approach addresses a critical unmet need in Parkinson's, where current therapies only manage symptoms. The company's platform has the potential to yield disease-modifying treatments that could slow or halt disease progression. Key risks include the inherent challenges of CNS drug development and the early stage of the company's programs. Nonetheless, ABLi's differentiated strategy and focus on validated kinase targets position it as a compelling candidate in the neurodegenerative disease space.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program40% success
• Q2 2026Preclinical Proof-of-Concept Data Publication60% success
• Q4 2026Series B Financing or Partnership Announcement45% success